JW Theriac

JW’s vision in oncology is to change the paradigm of cancer treatment and improve the quality of life of patients with cancer.

To achieve this, we are focused on the research and development of targeted anticancer therapies and immune cell therapies.

Beginning with the development of the first dendritic cell-based immune cell therapy for metastatic renal cell carcinoma, JW has deepened its understanding of immuno-oncology through differentiated clinical development programs across various cancer types.

We are also continuing research to identify biomarkers that can help predict which patients are most likely to benefit from targeted anticancer therapies and immune cell therapies.

In addition to its immuno-oncology portfolio, JW is investigating signaling mechanisms involved in tumor development and is developing oncology programs that target Wnt and STAT signaling pathways.

Cardiovascular diseases include all conditions related to the heart and blood vessels.

JW is seeking treatments that can improve cardiovascular care, with a focus on hyperlipidemia and hypertension, for patients whose lives are threatened by cardiovascular and metabolic diseases.

We are also committed to improving quality of life and addressing unmet medical needs.

In clinical studies involving Korean patients with acute myocardial infarction, Livalo (pitavastatin) demonstrated not only a reduction in major cardiac events but also improvement in blood glucose control, supporting its profile as a treatment with no increased risk of diabetes.

JW is also developing various combination products using its own technology to improve dosing convenience for patients with both hyperlipidemia and hypertension by enabling multiple required ingredients to be taken together.

In addition, JW is working to discover new treatments for metabolic diseases that are not adequately managed by existing therapies, based on molecular-level mechanism research.

By continuously expanding its expertise in immunology, JW is striving to develop innovative medicines for patients with diseases such as atopic dermatitis, gout, asthma, and idiopathic pulmonary fibrosis.

JW’s goal is to develop treatments that address the root causes of chronic inflammatory diseases at the molecular level, beyond conventional therapies that mainly relieve symptoms.

Regenerative medicine is a field of medicine that replaces or regenerates human cells, tissues, and organs to restore their original functions.

JW’s goal is to regenerate damaged areas by activating the body’s own recovery mechanisms in tissues and organs that were previously considered irrecoverable.

In particular, JW focuses on Wnt signaling and other pathways involved in stem cell growth, differentiation, and related signaling, and is working to develop fundamental molecular-level treatments in regenerative medicine for hair follicle regeneration as well as muscle and brain disorders.

Under the Rare Disease Management Act, a rare disease is defined as a disease affecting fewer than 20,000 patients, or a disease for which the number of affected patients is unknown due to difficulties in diagnosis.

JW is working to develop effective treatments for patients with rare diseases, including hemophilia.

Vision loss is a major health and social issue affecting more than one billion people worldwide. It can limit social interaction and independence, reduce a patient’s ability to work, and lead to depression and anxiety.

JW is working to discover new treatments based on molecular-level mechanism research for diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD), where current treatment options remain limited.